Status:
COMPLETED
Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)
Lead Sponsor:
Manhattan Eye, Ear & Throat Hospital
Collaborating Sponsors:
Alcon Research
Conditions:
Maculopathy, Age-Related
Eligibility:
All Genders
50+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety of combining juxtasclerally administered anecortave acetate 15 mg with triamcinolone acetate 4 mg administered intravitreally following photodynamic...
Eligibility Criteria
Inclusion
- A male or female with evidence of exudative age-related macular degeneration with clinical/angiographic/optical coherence tomography (OCT) findings of subfoveal choroidal neovascularization (CNV) which has not responded to current therapy
- Baseline best-corrected visual acuity (BCVA) 20/40 to 20/640
- Patient must be willing and able to comply with the protocol and provide informed consent.
Exclusion
- Patients on intravenous, subcutaneous, or anticoagulant therapy (with the exception of aspirin and antiplatelet therapy) and cannot take a 5 day holiday from therapy prior to the injection procedure. Note: Patients on oral anticoagulant therapy may be considered to participate if the physician responsible for monitoring the anticoagulant therapy agrees that the patient may take a 5 day holiday from therapy prior to each anecortave injection. The attending doctor must notify the principal investigator and this notification will be made part of the source documentation. Anticoagulant therapy may resume either the evening of or the morning after the injection procedure.
- Patient with known glaucoma or steroid induced ocular hypertension
- Intraocular pressures of 21 mmHg or greater at time of entry into the study
- Patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions
- Patients who have undergone intraocular surgery within last 2 months or capsulotomy within last month in study eye
- Patient participating in any other investigational drug study
- Inability to obtain photographs to document CNV (including difficulty with venous access)
- Concomitant oral steroids or topical ophthalmic steroid use
- Sub-Tenon's injection of steroids within the past 6 months
- Patient with significant liver disease or uremia
- Patient with known adverse reaction to indocyanine green, iodine, verteporfin, or triamcinolone
- Patient is pregnant or nursing
- Age less than 50 years old
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00211419
Last Update
October 24 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Manhattan Eye, Ear & Throat Hospital
New York, New York, United States, 10021